Your Content Goes Here Working Together to Save Lives NanoHarmonics Inc. concluded its discussions with ManpowerGroup Philippines Inc. successfully. The discussions ended with ManpowerGroup Philippines Inc. issuing a formal Letter of Intent to NanoHarmonics Inc. An actual contract shall be executed between the two companies once commercial terms are finalized based [...]

Your Content Goes Here More Bioavailability, Less Side-Effects NanoHarmonics is working with several biotech companies to develop, do clinical trials, secure regulatory compliance approvals, and commercialize improved drugs. We aim to reformulate and repurpose existing medicines for oncology, for infectious diseases as well as develop new ones in partnership with [...]

Your Content Goes Here The future of bio-diagnostics Quantum dots are nanoparticles that exhibit physical properties distinct from their bulk counterparts. They fluoresce into different colors, they can be excited to emit waves, and they can be tuned based on size. In 1998, a paper was published describing how Quantum Dots [...]

Your Content Goes Here NanoHarmonics on Drug Delivery Systems NanoHarmonics Inc., in line with its strategic plan of integrating cutting-edge drug delivery system along with its QDot bio-diagnostic devices and data platform, merged with Avagen Pharma. NANOHARMONICS INC. now owns 100% of Avagen Pharma Inc.  Avagen is the global licensee of [...]

Your Content Goes Here The future of bio-diagnostics Effective therapy relies on accurate and timely diagnostics – the more accurate and timely, the better the chances for effective treatment. Rapid and quantitative diagnostics is therefore key to the future of medical science, and the convergence of technologies in bio-diagnostics, data [...]

Your Content Goes Here Predictive Models GeneHarmonics Inc. is helping to develop population-based studies that can help collect data points to better understand infectious diseases that can hopefully be used to develop predictive models to fight them. The pilot will be designed around studies for Malaria - considered the number one [...]